Molbio Diagnostics IPO Allotment Expected, GMP Signals Listing Gain
Investors await final allotment for the Molbio Diagnostics IPO, a Rs 939.70-crore issue that saw strong subscription rates. The company plans to use IPO funds for infrastructure and research expansion.
Key takeaways
- The allotment for the Molbio Diagnostics IPO is expected on Thursday.
- The IPO was oversubscribed 70.26 times, with strong demand from institutional investors.
- Molbio Diagnostics plans to use IPO proceeds for infrastructure and research development.
- The company is scheduled to list on BSE and NSE on August 17.
- The grey market premium indicates an expected listing gain of approximately 20%.
The finalization of the allotment for the Molbio Diagnostics Initial Public Offering (IPO) is anticipated for Thursday. This Rs 939.70-crore public issue, which concluded its subscription period, has garnered significant investor interest. Preliminary indications from the grey market suggest a potential listing gain, with a premium of approximately 20% observed.
Molbio Diagnostics is slated to commence trading on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on August 17. The IPO, which ran from August 10 to August 12, was oversubscribed by 70.26 times. Institutional investors showed substantial demand, with Qualified Institutional Buyers (QIBs) subscribing 186.39 times their allocated portion, while Non-Institutional Investors (NIIs) subscribed 49.80 times and retail investors 12.96 times.
The total offering consisted of a fresh issue of 25 lakh shares valued at Rs 200 crore and an offer for sale (OFS) of 92 lakh shares totaling Rs 739.70 crore. Molbio Diagnostics had previously secured Rs 281.5 crore from anchor investors by allotting 34.87 lakh equity shares at Rs 807 per share, the upper limit of the IPO price band.
Funds raised through the IPO are earmarked for expanding the company's infrastructure and enhancing its research and manufacturing capabilities. A significant portion is allocated for developing a research and development facility and a Centre of Excellence. Additional investments will be made in plant and machinery for manufacturing facilities located in Goa and Visakhapatnam. The remaining proceeds will be used for general corporate purposes.
Molbio Diagnostics, established in October 2000, focuses on developing and commercializing rapid diagnostic solutions for various diseases. The company is recognized for its portable PCR-based diagnostic system, the Truenat platform, designed for quick and accurate results, particularly in areas with limited resources.
Sources reviewed
Project Chintan independently synthesized and analyzed information cross-checked across the sources listed above.
Related stories
SEBI Report: Anchor Investors Sell 50% of IPO Holdings After One Year
FTSE 100 Declines Amidst Mixed US Inflation Data and Mining Sector Weakness
NHS Faces 'Summer Surge' Amid Record A&E Visits and Heatwave Pressures
